Thioureidobutyronitrile - Innovation Pharmaceuticals

Drug Profile

Thioureidobutyronitrile - Innovation Pharmaceuticals

Alternative Names: Kevetrin

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellceutix
  • Developer Innovation Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Nitriles; Small molecules
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; Caspase 3 stimulants; Poly(ADP-ribose) polymerase modulators; Retinoblastoma protein modulators; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Retinoblastoma; Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Ovarian cancer

Highest Development Phases

  • Phase II Ovarian cancer
  • Preclinical Acute myeloid leukaemia
  • No development reported Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Glioblastoma; Head and neck cancer; Lung cancer; Lymphoma; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal cancer; Retinoblastoma; Solid tumours

Most Recent Events

  • 28 Dec 2017 Pharmacodynamics data from a phase IIa trial in Ovarian Cancer released by Innovation Pharmaceuticals
  • 10 Nov 2017 Innovation Pharmaceuticals completes a phase II trial in Ovarian cancer (Late stage disease, Second-line therapy or greater) in USA (NCT03042702)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top